Drugmaker pays $442m indoors Plavix patent case
Apotex Corp., Canadas biggest drugmaker, has paid the two brand-name drugmakers $442.2 million within indemnity meant for advertising a generic version of Plavix within 2006. Apotex launched its copycat version while it was still taking part in a cozy up to dispute with Bristol and Sanofi, partners who jointly souk Plavix. Apotex argued next to the point so as to scale patents on Plavix were worthless, responsibility whats called an at-risk launch of its generic version of Plavix. A federal say in a while ruled the Plavix patent was defensible, leading to the compensation payment.